WO2009157377A1 - Buccal anaesthetic - Google Patents

Buccal anaesthetic Download PDF

Info

Publication number
WO2009157377A1
WO2009157377A1 PCT/JP2009/061177 JP2009061177W WO2009157377A1 WO 2009157377 A1 WO2009157377 A1 WO 2009157377A1 JP 2009061177 W JP2009061177 W JP 2009061177W WO 2009157377 A1 WO2009157377 A1 WO 2009157377A1
Authority
WO
WIPO (PCT)
Prior art keywords
anesthetic
oral
container
dental
patient
Prior art date
Application number
PCT/JP2009/061177
Other languages
French (fr)
Japanese (ja)
Inventor
一也 中嶋
慶太 楠本
Original Assignee
田中 和美
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 田中 和美 filed Critical 田中 和美
Priority to JP2010517971A priority Critical patent/JPWO2009157377A1/en
Publication of WO2009157377A1 publication Critical patent/WO2009157377A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015Devices specially adapted for taking medicines
    • A61J7/0046Cups, bottles or bags

Definitions

  • the present invention relates to an intraoral anesthetic used for professional tooth cleaning, calculus removal, dental examination, dental treatment, oral surgery, or otolaryngology treatment.
  • Tooth surface cleaning by professionals professional mechanical tooth cleaning, hereinafter referred to as “PMTC”), dental removal (hereinafter referred to as “scaling”).
  • PMTC professional mechanical tooth cleaning
  • scaling periodontal disease examination, minor cutting, plaque removal and other dental examinations or treatments do not cause severe pain such as tooth extraction or large-scale cutting, but patients feel uncomfortable Pain occurs.
  • T.A It is often the subject of C, scaling, dental examination, dental treatment or oral surgery. Furthermore, these application-type anesthetics, spray-type anesthetics, and jelly-like anesthetics require a time of about 5 minutes from the time they are administered to a patient until the anesthetic effect is exerted, which impedes rapid treatment. Yes.
  • An object of the present invention is to provide an oral anesthetic agent that enables treatment.
  • P. M, T.M. C Scaling, Periodontal disease examination, Minor cutting, Dental removal such as plaque removal, Dental treatment, Oral surgery, Oral anaesthesia that can safely remove the discomfort experienced by patients I came up with a mouthwash as a dosage form of the agent. If it is the said dosage form, it will osmose
  • the present inventor further tackled the contradictory problem of effectiveness and safety of anesthesia, and examined a strict quantitative administration method of an anesthetic agent. Then, the present invention has been completed by conceiving a configuration in which a predetermined container is filled with only an amount of the oral anesthetic used in one dental treatment or the like.
  • the first invention for solving the above-described problem is A liquid oral anesthetic used during professional tooth cleaning, tartar removal, dental examination, dental treatment, oral surgery, or otolaryngology procedures, Contains anesthetics approved by the Pharmaceutical Affairs Law, The amount of the liquid oral anesthetic used in the single dental examination or dental treatment is filled in a predetermined container in a state of being blocked from the outside air, When performing oral anesthesia, the container is opened and the liquid oral anesthetic agent is administered to a patient, and then the oral anesthetic agent is treated in the form of gargle. Anesthetic.
  • the second invention is In addition to the anesthetic that has been approved by the Pharmaceutical Affairs Law, a bactericide that has been approved by the Pharmaceutical Affairs Law is contained.
  • the third invention is The intraoral anesthetic according to the first or second invention, wherein lidocaine hydrochloride is contained as an anesthetic that has been approved by the Pharmaceutical Affairs Law.
  • the fourth invention is: The oral anesthetic agent according to the second or third invention, characterized in that it contains chlorohexidine as a fungicide that has been approved by the Pharmaceutical Affairs Law.
  • the fifth invention is: The oral anesthetic according to any one of the first to fourth inventions, wherein a plastic portion container is used as the container.
  • P. M.M. T.A. C scaling, dental examination, dental treatment, oral surgery, or otolaryngology treatment is performed by a patient who gargles with the oral anesthetic according to the present invention, so that the patient's oral cavity is sufficient, and Since it is safely and rapidly anesthetized, P.P. M.M. T.A. C, scaling, dental examination, dental treatment, oral surgery, or otolaryngology procedures can be performed.
  • the anesthetics used for the oral anesthetic according to the present invention may be those that have already been approved by the pharmaceutical law (the Pharmaceutical Affairs Law in Japan) in the country where the oral anesthetic is used.
  • Examples thereof include lidocaine, epinephrine, mepivacaine hydrochloride, ethyl paraaminobenzoate, oxybuprocaine, tetracaine, procaine, diethylaminoethyl parabutylaminobenzoate, or a pharmaceutically acceptable salt thereof, or a mixture thereof.
  • lidocaine hydrochloride epinephrine, and mepivacaine hydrochloride are used.
  • the optimum concentration of the anesthetic varies depending on the drug type, but 2% to 3% is preferable for lidocaine hydrochloride and mepivacaine hydrochloride.
  • These anesthetics act on C-FIBER at the nerve endings and have the effect of instantly relieving pain such as the mild mucous membranes in the oral cavity that many patients feel uncomfortable.
  • the immediate alleviation of pain in the mucous membrane and the like has made it possible to reduce the unpleasant experience that patients feel during dental treatment and the uncomfortable feeling during injection. As a result, dentists can now perform treatment more safely.
  • Bactericidal agent / anti-inflammatory agent It is preferable to add a bactericidal agent or an anti-inflammatory agent to the oral anesthetic agent according to the present invention for the purpose of bactericidal / anti-inflammatory in the oral cavity. It can be expected to have an effect on periodontal disease and its prevention by using in combination with the cleaning aid described later.
  • the disinfectant and anti-inflammatory agent include chlorohexidine, azulene salt, tranexamic acid salt, carnosine salt, cetylpyridinium chloride, triclosan, methylene blue, povidone iodine, benzalkonium chloride, and ethanol.
  • addition of a fluorine mouthwash is also preferable.
  • pH adjuster In order for the anesthetic agent to act effectively, it is preferable to adjust the preparation to a predetermined pH when using the oral anesthetic agent. For example, it is preferable to adjust to pH 4 ⁇ 1 for lidocaine hydrochloride and pH 5.5 ⁇ 1 for mepivacaine hydrochloride. Therefore, it is preferable to add a pH adjuster.
  • Examples of the pH adjuster include acids such as hydrochloric acid, dilute hydrochloric acid, boric acid, phosphoric acid and salts thereof, citric acid, succinic acid, malic acid, tartaric acid, lactic acid, ascorbic acid, fumaric acid, maleic acid, gluconic acid, Examples thereof include organic acids such as glucuronic acid and acetic acid and salts thereof, and bases such as potassium hydroxide, calcium hydroxide, sodium hydroxide, magnesium hydroxide, sodium carbonate and sodium hydrogen carbonate. It may be a mixture of the acid and base.
  • the mixture of the organic acid of a citric acid and malic acid, sodium hydroxide, and sodium hydrogencarbonate is mentioned.
  • Thickener It is also preferable to add a thickener so that the oral anesthetic agent according to the present invention effectively stays in the oral cavity.
  • the thickener include glycerin, propylene glycol, hydroxyethyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, sodium alginate, and gelatin.
  • a bad breath inhibitor such as aspartame, stevia, thaumatin, erythritol, sorbitol, xylitol, and saccharin sodium can be blended.
  • sweeteners such as aspartame, stevia, thaumatin, erythritol, sorbitol, xylitol, and saccharin sodium can be blended.
  • fragrances such as lemon, orange, grapefruit, pine, banana, chocolate, yogurt, vanilla, menthol and the like can be blended.
  • various herbs, cinnamon bark, licorice, clove and other herbal medicines can be blended.
  • various vitamins such as vitamin C and vitamin E can be blended.
  • a solubilizer such as polyoxyethylene hydrogenated castor oil and a cleaning aid such as cocoyl arginine ethyl PCA can be blended.
  • Oral anesthetic agent dosage form according to the present invention is preferably an aqueous solution dosage form. This is because the oral anesthetic agent can be opened at the side of the patient and immediately administered to the patient to gargle. Then, the present inventors can administer the oral anesthetic agent to the patient in the form of gargle, so that the oral anesthetic agent according to the present invention is a conventional application-type anesthetic, spray-type anesthetic, jelly Compared to a state-of-the-art anesthetic, it is considered to exhibit an anesthetic effect quickly.
  • the liquid which is an oral anesthetic according to the present invention becomes a turbulent state in the oral cavity.
  • a sufficient amount of the drug can be quickly applied to a narrow part including a periodontal pocket and a tooth.
  • Rapid penetration of a sufficient amount of drug into the narrow part of the oral cavity and the rapid supply of anesthetic by the constant supply of fresh drug to the oral part other than the narrow part is achieved. It is thought to be a thing.
  • the intraoral anesthetic agent according to the present invention is prepared by sealing and storing an amount of the oral anesthetic agent used once per patient as one pack.
  • the container is preferably a disposable sealed container.
  • a portion type container, a bottle type container, an ampoule, etc. are mentioned.
  • FIG. 1 is a perspective view of an example of a portion type container
  • FIG. 2 is a perspective view of an example of a bottle type container with a lid.
  • the portion type container shown in FIG. 1 has a plastic lid (2) bonded to the upper part of a plastic cup-shaped container (1).
  • the oral anesthetic agent according to the present invention filled in the container part (1) is blocked from the outside air by the lid part (2). What is necessary is just to peel a cover part (2) from a container part (1) at the time of use of the oral cavity anesthetic which concerns on this invention.
  • the interval of the scale (9) is preferably 25%, 50%, 75% of the total content.
  • the upper part of the plastic bottle container (3) and the plastic lid (4) are in close contact with each other by screws.
  • the oral anesthetic agent according to the present invention filled in the container part (3) is blocked from the outside air by the lid part (4).
  • the lid (4) may be removed from the container (3).
  • the interval of the scale (9) is preferably 25%, 50%, 75% of the total content.
  • the ampule type container shown in FIG. 3 is a glass ampule container (5) filled with the oral anesthetic agent according to the present invention.
  • the oral anesthetic according to the present invention filled in the glass ampoule container (5) is blocked from the outside air.
  • the ampoule container head may be cut off and removed.
  • You may give a scale (9) to a container part (5) if desired.
  • the interval of the scale (9) is preferably 25%, 50%, 75% of the total content.
  • the portion type container shown in FIG. 4 has a plastic lid portion (8) bonded to the upper part of two or more plastic cup-shaped container portions (6) and (7).
  • the oral anesthetics according to the present invention filled in two or more container parts (6) and (7) are blocked from the outside air while being separated from each other by the lid part (8).
  • the lid (8) may be peeled off from the container (6) (7).
  • the container is suitable for the case where it is desired to keep each component separated until just before administration to a patient from the viewpoint of mixing stability, compatibility and the like of components contained in the oral anesthetic agent.
  • You may give a scale (9) to a container part (6) (7) if desired.
  • the interval of the scale (9) is preferably 25%, 50%, 75% of the total content.
  • the amount of oral anesthetic agent at one time is preferably 10 to 15 ml, more preferably 12 to 13 ml. It is done. Furthermore, for children, it is convenient to use the same oral anesthetic agent as that for adults, and to reduce the amount of oral anesthetic agent to 1 ⁇ 2 amount for adults, for example. Of course, the amount of the oral anesthetic agent can be the same as that for adults, and the concentration of the oral anesthetic agent can be halved for adults, for example.
  • the concentration of the oral anesthetic agent it is also preferable to pre-scale the container. For example, if a scale is provided at positions corresponding to 25%, 50%, and 75% of the total amount of the oral anesthetic agent, the dose to the patient can be easily adjusted.
  • P. of the present invention M.M. T.A.
  • Application to C scaling, dental treatment, oral surgery, or otolaryngology treatment
  • the present invention does not cause severe pain such as tooth extraction or large-scale cutting, but causes pain that makes the patient feel uncomfortable
  • C Scaling, Periodontal disease examination, Minor cutting, Dental removal or dental treatment such as plaque removal, etc.
  • P.I. M.M. T.A In the case of C, scaling, dental treatment, etc., a unique tingling pain occurs, making the patient feel uncomfortable.
  • the oral anesthetic agent according to the present invention is included in the patient's mouth immediately before the above-described treatment, and the patient side and the dentist / doctor side are comfortable and quick by garbling for about 10 seconds. You can share the treatment time.
  • Example 1 As an intraoral anesthetic according to Example 1, Leptospan S (containing 2% lidocaine hydrochloride and 0.00125% epinephrine) manufactured by Septdon was prepared. The oral anesthetic agent 12 ml shown in FIG. 1 is filled and sealed in a plastic portion type container (internal volume 12 ml), the lid of the portion type container is sealed, and the oral cavity according to Example 1 is sealed. An internal anesthetic was used.
  • M.M. T.A. C Scaling, Periodontal Examination, Dental Examination and Dental Treatment of Plaque Removal. According to interviews with the patient, the effect of anesthesia began immediately after gargle. The intensity of anesthesia was not so strong. M.M. T.A. C, scaling, periodontal disease test, the tingling sensation associated with the removal of plaque and the impression that mild pain was not felt.
  • an oral anesthetic is prepared right next to the patient, and appropriate oral anesthesia is treated for the patient simply by gargleing the oral anesthetic.
  • both the patient and the dentist were relieved and were able to perform dental examination and treatment in a relaxed state.
  • the oral anesthetic agent according to the present invention has been described by taking dental examination or dental treatment with relatively light pain such as C, scaling, periodontal disease examination, minor cutting, and plaque removal as an example.
  • the intraoral anesthetic according to the present invention can also be used as an anesthetic for oral surgery and otolaryngology treatment.
  • it can also be used as a preliminary anesthetic agent that relieves the pain of anesthesia injection performed prior to treatment such as extraction with strong pain.
  • Container part (2) Lid part (3) Container part (4) Lid part (5) Container part (6) Container part (7) Container part (8) Lid part (9) Scale

Abstract

Disclosed is a buccal anaesthetic, which is a liquid buccal anaesthetic used for dental examination or dental treatment, containing an anaesthetic authorized under the Pharmaceutical Affairs Law. A given container is filled with a quantity of afore­mentioned liquid buccal anaesthetic used for a single dental examination or dental treatment, in a state in which outside air is excluded, and when buccal anaesthesia is carried out, the aforementioned liquid buccal anaesthetic is administered to the patient by unsealing the aforementioned container, after which this buccal anaesthetic is used as a gargle.

Description

口腔内麻酔剤Oral anesthetic
 本発明は、専門家による歯面清掃、歯石除去、歯科検査、歯科治療、口腔外科手術、または耳鼻咽喉科処置の際に用いられる口腔内麻酔剤に関するものである。 The present invention relates to an intraoral anesthetic used for professional tooth cleaning, calculus removal, dental examination, dental treatment, oral surgery, or otolaryngology treatment.
 殆どの、専門家による歯面清掃(プロフェッショナル メカニカル トゥース クリーニング、以下、「P.M.T.C」と記載する場合がある。)、歯科除去(以下、「スケーリング」と記載する場合がある。)、歯科検査、歯科治療、口腔外科手術、または、耳鼻咽喉科処置の際に患者は痛みを感ずる。口腔内は知覚の敏感な場所であるので、激しい痛みはもちろん、僅かな痛みであっても患者の受ける精神的負担は大きなものである。そこで、当該痛みを除去または軽減するために麻酔剤が投与される。
 例えば、抜歯や大規模な切削等の際は、激しい痛みが発生するので、所定の麻酔剤が歯茎へ注射等により投与される。
 これに対し、P.M.T.C、スケーリング、歯周病検査、軽微な切削、歯垢の除去等の歯科検査または歯科治療においては、抜歯や大規模な切削等の様な激しい痛みは発生しないものの、患者が不快感を覚える痛みが発生する。
Tooth surface cleaning by professionals (professional mechanical tooth cleaning, hereinafter referred to as “PMTC”), dental removal (hereinafter referred to as “scaling”). ), Patients feel pain during dental examination, dental treatment, oral surgery, or otolaryngology procedures. Since the oral cavity is a sensitive place, the patient suffers a great mental burden even with slight pain as well as severe pain. Therefore, an anesthetic is administered to remove or alleviate the pain.
For example, during tooth extraction or large-scale cutting, since severe pain occurs, a predetermined anesthetic is administered to the gums by injection or the like.
On the other hand, P.I. M.M. T.A. C, scaling, periodontal disease examination, minor cutting, plaque removal and other dental examinations or treatments do not cause severe pain such as tooth extraction or large-scale cutting, but patients feel uncomfortable Pain occurs.
 当該状況の下で、先進的な歯科医師や医師は、P.M.T.C、スケーリング、歯科検査、歯科治療、口腔外科手術、または、耳鼻咽喉科処置に先立ち、患者に塗布型麻酔剤、噴霧型麻酔剤、または、ゼリー状麻酔剤を投与し、当該歯科検査等に起因する痛みの除去を行っている(例えば、特許文献1参照)。 Under such circumstances, advanced dentists and doctors M.M. T.A. Prior to C, scaling, dental examination, dental treatment, oral surgery, or otolaryngology treatment, a coated anesthetic, spray-type anesthetic, or jelly-like anesthetic is administered to the patient for the dental examination, etc. The resulting pain is removed (for example, see Patent Document 1).
特開2006-16067号公報JP 2006-16067 A
 ところが、本発明者の検討によると、以下の課題が明らかとなった。
 まず、塗布型麻酔では患者への投与量が定量化されない、という課題が明らかとなった。
 この結果、投与量が不足すれば麻酔の効きが不足し患者に不快感を与えてしまう。これに対し、投与量が過剰であれば、外用麻酔とはいえ、患者の健康に悪影響を及ぼす可能性がある。
 次に、ゼリー状麻酔剤であれば、患者への投与量を定量化することは容易である。しかし、ゼリー状麻酔剤はその剤型に起因して、麻酔を施したい箇所に到達しない場合がある。例えば、歯と歯の間の隙間、歯周ポケット等の領域には効きが悪い。ところが、正にこれらの箇所こそが、P.M.T.C、スケーリング、歯科検査、歯科治療、または、口腔外科手術の対象である場合が多い。
 さらに、これら塗布型麻酔剤、噴霧型麻酔剤、ゼリー状麻酔剤は、患者に投与してから麻酔効果が発揮される迄、5分間位の時間を必要とし、迅速な処置の障害となっている。
However, according to the study of the present inventor, the following problems have been clarified.
First, the subject that the dose to a patient was not quantified by the application type | formula anesthesia became clear.
As a result, if the dose is insufficient, the effect of anesthesia is insufficient and the patient is uncomfortable. On the other hand, if the dose is excessive, it may adversely affect the health of the patient even though it is an external anesthetic.
Next, if it is a jelly-like anesthetic, it is easy to quantify the dosage to a patient. However, jelly-like anesthetics may not reach the location where anesthesia is desired due to the dosage form. For example, it is not effective in areas such as gaps between teeth and periodontal pockets. However, exactly these points are M.M. T.A. It is often the subject of C, scaling, dental examination, dental treatment or oral surgery.
Furthermore, these application-type anesthetics, spray-type anesthetics, and jelly-like anesthetics require a time of about 5 minutes from the time they are administered to a patient until the anesthetic effect is exerted, which impedes rapid treatment. Yes.
 本発明は、上記事情を考慮し、P.M.T.C、スケーリング、歯周病検査、軽微な切削、歯垢の除去等の歯科検査、歯科治療、口腔外科手術、または、耳鼻咽喉科処置に際し、患者が受ける不快感を安全に除去し、迅速な処置を可能とする口腔内麻酔剤の提供を目的とする。 In the present invention, in consideration of the above circumstances, P.I. M.M. T.A. C, Scaling, Periodontal disease inspection, Minor cutting, Dental removal such as plaque removal, Dental treatment, Oral surgery, or Otolaryngology procedure, safely remove the discomfort experienced by the patient and promptly An object of the present invention is to provide an oral anesthetic agent that enables treatment.
 上述の課題を解決するため、本発明者は鋭意研究を行った。
 そして、P.M,T.C、スケーリング、歯周病検査、軽微な切削、歯垢の除去等の歯科検査、歯科治療、口腔外科手術、または、耳鼻咽喉科処置に際し、患者が受ける不快感を安全に除去出来る口腔内麻酔剤の剤型として口漱剤に想到した。当該剤型であれば、例えば、歯と歯の間の隙間、歯周ポケット等の領域にも容易に浸透し、10秒間位の短時間で麻酔剤の効果を発揮させることが出来る。
In order to solve the above-mentioned problems, the present inventor has conducted intensive research.
P. M, T.M. C, Scaling, Periodontal disease examination, Minor cutting, Dental removal such as plaque removal, Dental treatment, Oral surgery, Oral anaesthesia that can safely remove the discomfort experienced by patients I came up with a mouthwash as a dosage form of the agent. If it is the said dosage form, it will osmose | permeate easily also to areas, such as the space | gap between teeth, a periodontal pocket, etc., and the effect of an anesthetic can be exhibited in about 10 second short time.
 ここで、本発明者はさらに、麻酔の効きと安全性という2律背反の問題に取り組み、麻酔剤の厳密な定量投与法を検討した。そして、1回の歯科治療等の際に用いられる量の口腔内麻酔剤のみを、予め所定の容器に充填しておくという構成に想到し、本発明を完成した。 Here, the present inventor further tackled the contradictory problem of effectiveness and safety of anesthesia, and examined a strict quantitative administration method of an anesthetic agent. Then, the present invention has been completed by conceiving a configuration in which a predetermined container is filled with only an amount of the oral anesthetic used in one dental treatment or the like.
 即ち、上述の課題を解決するための第1の発明は、
 専門家による歯面清掃、歯石除去、歯科検査、歯科治療、口腔外科手術、または、耳鼻咽喉科処置の際に用いられる液体の口腔内麻酔剤であって、
 薬事法承認取得済みの麻酔薬を含有し、
 前記1回の歯科検査または歯科治療の際に用いられる量の前記液体の口腔内麻酔剤が、外気と遮断された状態で所定の容器に充填されたものであり、
 口腔内麻酔を実施する際には、前記容器を開封して前記液体の口腔内麻酔剤患者に投与後、当該口腔内麻酔剤をうがいさせる形で施療するものであることを特徴とする口腔内麻酔剤である。
That is, the first invention for solving the above-described problem is
A liquid oral anesthetic used during professional tooth cleaning, tartar removal, dental examination, dental treatment, oral surgery, or otolaryngology procedures,
Contains anesthetics approved by the Pharmaceutical Affairs Law,
The amount of the liquid oral anesthetic used in the single dental examination or dental treatment is filled in a predetermined container in a state of being blocked from the outside air,
When performing oral anesthesia, the container is opened and the liquid oral anesthetic agent is administered to a patient, and then the oral anesthetic agent is treated in the form of gargle. Anesthetic.
 第2の発明は、
 前記薬事法承認取得済みの麻酔薬に加え、薬事法承認取得済みの殺菌剤を含有していることを特徴とする第1の発明に記載の口腔内麻酔剤である。 
The second invention is
In addition to the anesthetic that has been approved by the Pharmaceutical Affairs Law, a bactericide that has been approved by the Pharmaceutical Affairs Law is contained.
 第3の発明は、
 前記薬事法承認取得済みの麻酔薬として塩酸リドカインを含有していることを特徴とする第1または第2の発明に記載の口腔内麻酔剤である。 
The third invention is
The intraoral anesthetic according to the first or second invention, wherein lidocaine hydrochloride is contained as an anesthetic that has been approved by the Pharmaceutical Affairs Law.
 第4の発明は、
 前記薬事法承認取得済みの殺菌剤としてクロロヘキシジンを含有していることを特徴とする第2または第3の発明に記載の口腔内麻酔剤である。 
The fourth invention is:
The oral anesthetic agent according to the second or third invention, characterized in that it contains chlorohexidine as a fungicide that has been approved by the Pharmaceutical Affairs Law.
 第5の発明は、
 前記容器として、プラスチック製のポーション容器を用いていることを特徴とする第1から第4の発明のいずれかに記載の口腔内麻酔剤である。 
The fifth invention is:
The oral anesthetic according to any one of the first to fourth inventions, wherein a plastic portion container is used as the container.
 P.M.T.C、スケーリング、歯科検査、歯科治療、口腔外科手術、または、耳鼻咽喉科処置を受ける患者が、本発明に係る口腔内麻酔剤でうがいをすることにより、当該患者の口腔内が十分、且つ、安全、且つ、迅速に麻酔されるので、患者に不快感や危険性を与えることなく、P.M.T.C、スケーリング、歯科検査、歯科治療、口腔外科手術、または、耳鼻咽喉科処置を施すことが出来る。 P. M.M. T.A. C, scaling, dental examination, dental treatment, oral surgery, or otolaryngology treatment is performed by a patient who gargles with the oral anesthetic according to the present invention, so that the patient's oral cavity is sufficient, and Since it is safely and rapidly anesthetized, P.P. M.M. T.A. C, scaling, dental examination, dental treatment, oral surgery, or otolaryngology procedures can be performed.
 以下、本発明の実施形態について詳細に説明する。
1.麻酔薬
 本発明に係る口腔内麻酔剤に用いる麻酔薬は、当該口腔内麻酔剤が用いられる国において、医薬品に関する法律(日本国であれば薬事法)承認取得済みのものであれば良い。例えば、リドカイン、エピネフリン、塩酸メピバカイン、パラアミノ安息香酸エチル、オキシブプロカイン、テトラカイン、プロカイン、パラブチルア ミノ安息香酸ジエチルアミノエチルまたはこれらの薬学上許容される塩が挙げられ、これらの混合物であってもよい。好ましくは、塩酸リドカイン、エピネフリン、塩酸メピバカインが挙げられる。
 麻酔薬の最適濃度は薬種によって異なるが、塩酸リドカイン、塩酸メピバカインであれば2%から3%が好ましい。
 これらの麻酔薬は、神経の末端のC-FIBERに作用し、多くの患者が不快に感じる口腔内の軽度な粘膜等の痛みを即座に緩和する効果を有する。当該粘膜等の痛みの即座緩和効果により、患者が歯科治療などの際に感じる不快な経験や、注射時の不快感も減少させることが可能となった。この結果、歯科医師も、より安全に施術可能となった。
Hereinafter, embodiments of the present invention will be described in detail.
1. Anesthetics The anesthetics used for the oral anesthetic according to the present invention may be those that have already been approved by the pharmaceutical law (the Pharmaceutical Affairs Law in Japan) in the country where the oral anesthetic is used. Examples thereof include lidocaine, epinephrine, mepivacaine hydrochloride, ethyl paraaminobenzoate, oxybuprocaine, tetracaine, procaine, diethylaminoethyl parabutylaminobenzoate, or a pharmaceutically acceptable salt thereof, or a mixture thereof. . Preferably, lidocaine hydrochloride, epinephrine, and mepivacaine hydrochloride are used.
The optimum concentration of the anesthetic varies depending on the drug type, but 2% to 3% is preferable for lidocaine hydrochloride and mepivacaine hydrochloride.
These anesthetics act on C-FIBER at the nerve endings and have the effect of instantly relieving pain such as the mild mucous membranes in the oral cavity that many patients feel uncomfortable. The immediate alleviation of pain in the mucous membrane and the like has made it possible to reduce the unpleasant experience that patients feel during dental treatment and the uncomfortable feeling during injection. As a result, dentists can now perform treatment more safely.
2.殺菌剤・消炎剤
 本発明に係る口腔内麻酔剤へは、口腔内の殺菌・消炎を目的として、殺菌剤や消炎剤を添加しておくことが好ましい。後述する清掃助剤との併用により歯周病と、その予防にも効果を期待出来る。当該殺菌剤や消炎剤としては、例えば、クロロヘキシジン、アズレン塩、トラネキサム酸塩、カルノシン塩、塩化セチルピリジニウム、トリクロサン、メチレンブルー、ポビドンヨード、塩化ベンザルコニウム、エタノール等がある。さらに、フッ素洗口剤の添加も好ましい。
2. Bactericidal agent / anti-inflammatory agent It is preferable to add a bactericidal agent or an anti-inflammatory agent to the oral anesthetic agent according to the present invention for the purpose of bactericidal / anti-inflammatory in the oral cavity. It can be expected to have an effect on periodontal disease and its prevention by using in combination with the cleaning aid described later. Examples of the disinfectant and anti-inflammatory agent include chlorohexidine, azulene salt, tranexamic acid salt, carnosine salt, cetylpyridinium chloride, triclosan, methylene blue, povidone iodine, benzalkonium chloride, and ethanol. Furthermore, addition of a fluorine mouthwash is also preferable.
3.pH調整剤
 前記麻酔剤が効果的に作用するために、口腔内麻酔剤の使用時において、製剤を所定のpHに調整しておくことが好ましい。例えば、塩酸リドカインであればpH4±1、塩酸メピバカインであればpH5.5±1に調整することが好ましい。そこで、pH調整剤を添加しておくことが好ましい。当該pH調整剤としては、例えば、塩酸、希塩酸、ホウ酸、リン酸等の酸およびその塩、クエン酸、コハク酸、リンゴ酸、酒石酸、乳酸、アスコルビン酸、フマル酸、マレイン酸、グルコン酸、グルクロン酸、酢酸等の有機酸およびその塩、水酸化カリウム、水酸化カルシウム、水酸化ナトリウム、水酸化マグネシウム、炭酸ナトリウム、炭酸水素ナトリウム等の塩基が挙げられる。前記酸、塩基の混合物であっても良い。好ましくはクエン酸、リンゴ酸の有機酸と、水酸化ナトリウム、炭酸水素ナトリウムとの混合物が挙げられる。
3. pH adjuster In order for the anesthetic agent to act effectively, it is preferable to adjust the preparation to a predetermined pH when using the oral anesthetic agent. For example, it is preferable to adjust to pH 4 ± 1 for lidocaine hydrochloride and pH 5.5 ± 1 for mepivacaine hydrochloride. Therefore, it is preferable to add a pH adjuster. Examples of the pH adjuster include acids such as hydrochloric acid, dilute hydrochloric acid, boric acid, phosphoric acid and salts thereof, citric acid, succinic acid, malic acid, tartaric acid, lactic acid, ascorbic acid, fumaric acid, maleic acid, gluconic acid, Examples thereof include organic acids such as glucuronic acid and acetic acid and salts thereof, and bases such as potassium hydroxide, calcium hydroxide, sodium hydroxide, magnesium hydroxide, sodium carbonate and sodium hydrogen carbonate. It may be a mixture of the acid and base. Preferably, the mixture of the organic acid of a citric acid and malic acid, sodium hydroxide, and sodium hydrogencarbonate is mentioned.
4.増粘剤
 本発明に係る口腔内麻酔剤が、口腔内に効果的に滞留するように増粘剤を添加しておくことも好ましい。当該増粘剤としては、例えば、グリセリン、プロピレングリコール、ヒドロキシエチルセルロース、ヒドロキシエチルメチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、アルギン酸ナトリウム、ゼラチンが挙げられる。
4). Thickener It is also preferable to add a thickener so that the oral anesthetic agent according to the present invention effectively stays in the oral cavity. Examples of the thickener include glycerin, propylene glycol, hydroxyethyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, sodium alginate, and gelatin.
5.その他の添加物
 本発明に係る口腔内麻酔剤の使用感を向上させるため、口臭防止剤、清涼剤、消毒剤、香料、可溶化剤、清掃助剤、着色剤等、の添加も好ましい構成である。
 例えば、アスパルテーム、ステビア、ソーマチン、エリスリトール、ソルビトール、キシリトール、サッカリンナトリウム等の甘味料を配合することができる。また、例えば、レモン、オレンジ、グレープフルーツ、パイン、バナナ、チョコレート、ヨーグルト、バニラ、メントール等の香料を配合することができる。
 また、例えば、各種ハーブ、桂皮、甘草、丁字等の生薬を配合することができる。また、例えば、ビタミンC、ビタミンE等の各種ビタミンを配合することができる。
 さらに、ポリオキシエチレン硬化ヒマシ油等の可溶化剤、ココイルアルギニンエチルPCA等の清掃助剤を配合することができる。
5). Other additives In order to improve the feeling of use of the oral anesthetic according to the present invention, addition of a bad breath inhibitor, a refreshing agent, a disinfectant, a fragrance, a solubilizer, a cleaning aid, a colorant, etc. is also a preferred configuration. is there.
For example, sweeteners such as aspartame, stevia, thaumatin, erythritol, sorbitol, xylitol, and saccharin sodium can be blended. In addition, for example, fragrances such as lemon, orange, grapefruit, pine, banana, chocolate, yogurt, vanilla, menthol and the like can be blended.
In addition, for example, various herbs, cinnamon bark, licorice, clove and other herbal medicines can be blended. Further, for example, various vitamins such as vitamin C and vitamin E can be blended.
Further, a solubilizer such as polyoxyethylene hydrogenated castor oil and a cleaning aid such as cocoyl arginine ethyl PCA can be blended.
6.本発明に係る口腔内麻酔剤の剤型
(1)本発明に係る口腔内麻酔剤の剤型は、水溶液の剤型とすることが好ましい。当該口腔内麻酔剤を、患者の脇で開封して直ちに患者へ投与し、うがいさせることができるからである。そして、本発明者等は、当該口腔内麻酔剤が、うがいの形式で患者に投与されることで、本発明に係る口腔内麻酔剤が、従来の塗布型麻酔剤、噴霧型麻酔剤、ゼリー状麻酔剤に較べ、迅速に麻酔効果を発揮するものであると考えている。
6). Oral anesthetic agent dosage form according to the present invention (1) The oral anesthetic agent dosage form according to the present invention is preferably an aqueous solution dosage form. This is because the oral anesthetic agent can be opened at the side of the patient and immediately administered to the patient to gargle. Then, the present inventors can administer the oral anesthetic agent to the patient in the form of gargle, so that the oral anesthetic agent according to the present invention is a conventional application-type anesthetic, spray-type anesthetic, jelly Compared to a state-of-the-art anesthetic, it is considered to exhibit an anesthetic effect quickly.
 うがいには、液体を含んで口を閉じ、頬を膨らませたり元に戻したりを交互に素早く行ってすすぐ、所謂「ブクブクうがい」と、液体を含んで口を開け、上を向いて息を吐く、所謂「ガラガラうがい」とがある。いずれのうがいであっても、本発明に係る口腔内麻酔剤である液体は口腔内で乱流状態となり、例えば、歯周ポケット、歯間を始めとする狭隘部分に十分な量の薬剤が素早く浸透する。この口腔内狭隘部分への十分量の薬剤の素早い浸透、および、当該狭隘部分以外の口腔部分であっても、新鮮な薬剤が常に十分に供給されることにより、迅速な麻酔効果が発揮されるものであると考えられる。 To gargle, close the mouth with liquid, quickly swell and return to the cheeks, and quickly rinse, open the mouth with liquid, so-called `` buzz gargle '' and exhale upwards There is a so-called "rattle gargle". Whatever the gargle, the liquid which is an oral anesthetic according to the present invention becomes a turbulent state in the oral cavity. For example, a sufficient amount of the drug can be quickly applied to a narrow part including a periodontal pocket and a tooth. To penetrate. Rapid penetration of a sufficient amount of drug into the narrow part of the oral cavity and the rapid supply of anesthetic by the constant supply of fresh drug to the oral part other than the narrow part is achieved. It is thought to be a thing.
 具体的には、従来の塗布型麻酔剤、噴霧型麻酔剤、ゼリー状麻酔剤の場合、患者に投与してから十分な麻酔効果が得られるまで、5分間以上の時間が必要であったのに対し、本発明に係る口腔内麻酔剤の場合、患者に投与してから10秒間程度の時間で、直ちに十分な麻酔効果が得られた。
 そして、当該口腔内麻酔剤は、医師の管理下で患者に投与され約10秒間のうがい後、医師の指示により患者が直ちに口腔から吐き出すことで、速やかに排出される。
Specifically, in the case of the conventional application-type anesthetic, spray-type anesthetic, and jelly-like anesthetic, it took 5 minutes or more until a sufficient anesthetic effect was obtained after administration to the patient. On the other hand, in the case of the oral anesthetic according to the present invention, a sufficient anesthetic effect was immediately obtained in about 10 seconds after administration to the patient.
Then, the oral anesthetic agent is administered to the patient under the management of the doctor, and after gargle for about 10 seconds, the patient immediately exhales from the oral cavity according to the doctor's instruction, and is quickly discharged.
(2)本発明に係る口腔内麻酔剤は、1人の患者に1回使用する分量の口腔内麻酔剤を、1パックとして密封保存しておくものである。当該形態をとることで、口腔内麻酔剤の使用量の過不足を回避することを第1の目的としている。さらに、当該形態をとり、患者の脇で適量の水に希釈して使用する形態をとることで、患者に安心感と清潔感とを与えることを目的としている。
 従って、容器は使い捨ての密封型容器が好ましい。具体的には、ポーションタイプの容器、ボトルタイプの容器、アンプル等が挙げられる。図1にポーションタイプの容器例の斜視図、図2に蓋付きのボトルタイプの容器例の斜視図を示す。
(2) The intraoral anesthetic agent according to the present invention is prepared by sealing and storing an amount of the oral anesthetic agent used once per patient as one pack. By taking the said form, it aims at avoiding the excess and deficiency of the usage-amount of an oral anesthetic agent. Furthermore, it is intended to give the patient a sense of security and cleanliness by taking the form and using the form diluted with an appropriate amount of water on the side of the patient.
Therefore, the container is preferably a disposable sealed container. Specifically, a portion type container, a bottle type container, an ampoule, etc. are mentioned. FIG. 1 is a perspective view of an example of a portion type container, and FIG. 2 is a perspective view of an example of a bottle type container with a lid.
 図1に示すポーションタイプの容器は、プラスチック製のカップ状の容器部(1)の上部に、プラスチック製の蓋部(2)が接着しているものである。容器部(1)に充填された本発明に係る口腔内麻酔剤は、蓋部(2)によって外気から遮断される。本発明に係る口腔内麻酔剤の使用時には、蓋部(2)を容器部(1)から剥がせば良い。
 所望により容器部(1)に目盛り(9)を付与しても良い。当該目盛り(9)間隔は、内容物全量の25%、50%、75%とすること等が好ましい。
The portion type container shown in FIG. 1 has a plastic lid (2) bonded to the upper part of a plastic cup-shaped container (1). The oral anesthetic agent according to the present invention filled in the container part (1) is blocked from the outside air by the lid part (2). What is necessary is just to peel a cover part (2) from a container part (1) at the time of use of the oral cavity anesthetic which concerns on this invention.
You may give a scale (9) to a container part (1) if desired. The interval of the scale (9) is preferably 25%, 50%, 75% of the total content.
 図2に示すボトルタイプの容器は、プラスチック製のボトルの容器部(3)の上部と、プラスチック製の蓋部(4)とが、ねじによって密着しているものである。容器部(3)に充填された本発明に係る口腔内麻酔剤は、蓋部(4)によって外気から遮断される。本発明に係る口腔内麻酔剤の使用時には、蓋部(4)を容器部(3)から外せば良い。
 所望により容器部(3)に目盛り(9)を付与しても良い。当該目盛り(9)間隔は、内容物全量の25%、50%、75%とすること等が好ましい。
In the bottle type container shown in FIG. 2, the upper part of the plastic bottle container (3) and the plastic lid (4) are in close contact with each other by screws. The oral anesthetic agent according to the present invention filled in the container part (3) is blocked from the outside air by the lid part (4). When using the oral anesthetic according to the present invention, the lid (4) may be removed from the container (3).
You may give a scale (9) to a container part (3) if desired. The interval of the scale (9) is preferably 25%, 50%, 75% of the total content.
 図3に示すアンプルタイプの容器は、ガラス製のアンプル容器(5)に本発明に係る口腔内麻酔剤が充填されているものである。ガラス製のアンプル容器(5)に充填された本発明に係る口腔内麻酔剤は外気から遮断される。本発明に係る口腔内麻酔剤の使用時には、アンプル容器頭部を切断して外せば良い。
 所望により容器部(5)に目盛り(9)を付与しても良い。当該目盛り(9)間隔は、内容物全量の25%、50%、75%とすること等が好ましい。
The ampule type container shown in FIG. 3 is a glass ampule container (5) filled with the oral anesthetic agent according to the present invention. The oral anesthetic according to the present invention filled in the glass ampoule container (5) is blocked from the outside air. When using the oral anesthetic according to the present invention, the ampoule container head may be cut off and removed.
You may give a scale (9) to a container part (5) if desired. The interval of the scale (9) is preferably 25%, 50%, 75% of the total content.
 図4に示すポーションタイプの容器は、2つ以上のプラスチック製のカップ状の容器部(6)(7)の上部に、プラスチック製の蓋部(8)が接着しているものである。2つ以上の容器部(6)(7)に充填された本発明に係る口腔内麻酔剤は、蓋部(8)によって互いに分離されながら外気から遮断される。本発明に係る口腔内麻酔剤の使用時には、蓋部(8)を容器部(6)(7)から剥がせば良い。
 当該容器は、口腔内麻酔剤の含有成分の混合安定性、相溶性等の観点から、患者への投与直前まで、各成分を分離した状態にしておきたい場合に適したものである。
 所望により容器部(6)(7)に目盛り(9)を付与しても良い。当該目盛り(9)間隔は、内容物全量の25%、50%、75%とすること等が好ましい。
The portion type container shown in FIG. 4 has a plastic lid portion (8) bonded to the upper part of two or more plastic cup-shaped container portions (6) and (7). The oral anesthetics according to the present invention filled in two or more container parts (6) and (7) are blocked from the outside air while being separated from each other by the lid part (8). When using the oral anesthetic according to the present invention, the lid (8) may be peeled off from the container (6) (7).
The container is suitable for the case where it is desired to keep each component separated until just before administration to a patient from the viewpoint of mixing stability, compatibility and the like of components contained in the oral anesthetic agent.
You may give a scale (9) to a container part (6) (7) if desired. The interval of the scale (9) is preferably 25%, 50%, 75% of the total content.
 一回の口腔内麻酔剤量は、患者のうがいのし易さ、口腔内麻酔剤充填済み容器の保管の容易さ、操作性等を考えると10~15ml、さらには12~13mlが好ましいと考えられる。さらに、小児用としては、成人用と同じ口腔内麻酔剤を用い、一回の口腔内麻酔剤量を、例えば、成人用の1/2量とする対応が便宜である。勿論、一回の口腔内麻酔剤量を成人用と同じとし、口腔内麻酔剤の濃度を、例えば、成人用の1/2とする対応も可能である。当該口腔内麻酔剤の濃度を調整する観点から、上述したように、容器に予め目盛りを付与しておくことも好ましい構成である。例えば、当該口腔内麻酔剤全量の25%、50%、75%相当の位置に目盛りを付与しておけば、患者への投与量を容易に調整することが出来る。 Considering the ease of gargle of the patient, the ease of storage of the container filled with the oral anesthetic, operability, etc., it is considered that the amount of oral anesthetic agent at one time is preferably 10 to 15 ml, more preferably 12 to 13 ml. It is done. Furthermore, for children, it is convenient to use the same oral anesthetic agent as that for adults, and to reduce the amount of oral anesthetic agent to ½ amount for adults, for example. Of course, the amount of the oral anesthetic agent can be the same as that for adults, and the concentration of the oral anesthetic agent can be halved for adults, for example. From the viewpoint of adjusting the concentration of the oral anesthetic agent, as described above, it is also preferable to pre-scale the container. For example, if a scale is provided at positions corresponding to 25%, 50%, and 75% of the total amount of the oral anesthetic agent, the dose to the patient can be easily adjusted.
7.本発明のP.M.T.C、スケーリング、歯科治療、口腔外科手術、または、耳鼻咽喉科処置への適用
 本発明は、抜歯や大規模な切削等の様な激しい痛みは発生しないものの、患者が不快感を覚える痛みが発生する、P.M.T.C、スケーリング、歯周病検査、軽微な切削、歯垢の除去等の歯科検査または歯科治療、口腔外科手術、または、耳鼻咽喉科処置に最適なものである。
 これらのP.M.T.C、スケーリング、歯科治療等の際には、独特のチクチクした痛みが発生し、患者に不快な思いをさせている。さらに、近年、歯科領域において口腔内の軟組織および硬組織を対象とした様々な波長を有する歯科用レーザーの一部が保険適用となった。これに伴い、今後は、歯科用レーザー施療が多用されると予想される。本発明は、当該レーザー施療の際、患者の不快感を取り除く手段として最適なものである。
 具体的には、上述した施療の直前に、本発明に係る口腔内麻酔剤を患者の口に含ませ、10秒間程度うがいさせることで、患者側も、歯科医師・医師側も、快適且つ迅速な治療時間を共有することができる。
7). P. of the present invention. M.M. T.A. Application to C, scaling, dental treatment, oral surgery, or otolaryngology treatment The present invention does not cause severe pain such as tooth extraction or large-scale cutting, but causes pain that makes the patient feel uncomfortable P. M.M. T.A. C, Scaling, Periodontal disease examination, Minor cutting, Dental removal or dental treatment such as plaque removal, etc., It is most suitable for oral surgery or otolaryngology treatment.
These P.I. M.M. T.A. In the case of C, scaling, dental treatment, etc., a unique tingling pain occurs, making the patient feel uncomfortable. Furthermore, in recent years, some dental lasers having various wavelengths for soft and hard tissues in the oral cavity have been covered by insurance in the dental field. Along with this, it is expected that dental laser treatment will be frequently used in the future. The present invention is optimal as a means for removing patient discomfort during the laser treatment.
Specifically, the oral anesthetic agent according to the present invention is included in the patient's mouth immediately before the above-described treatment, and the patient side and the dentist / doctor side are comfortable and quick by garbling for about 10 seconds. You can share the treatment time.
(実施例1)
 実施例1に係る口腔内麻酔剤として、セプトドント社製リグノスパンS(塩酸リドカイン2%、エピネフリン0.00125%含有)を準備した。
 当該口腔内麻酔剤12mlを、図1に示す、プラスチック製のポーションタイプの容器(内容量12ml)に充填して密封し、当該ポーションタイプの容器の蓋を密閉して、実施例1に係る口腔内麻酔剤とした。
Example 1
As an intraoral anesthetic according to Example 1, Leptospan S (containing 2% lidocaine hydrochloride and 0.00125% epinephrine) manufactured by Septdon was prepared.
The oral anesthetic agent 12 ml shown in FIG. 1 is filled and sealed in a plastic portion type container (internal volume 12 ml), the lid of the portion type container is sealed, and the oral cavity according to Example 1 is sealed. An internal anesthetic was used.
 歯科医師が、患者の脇で、製造した実施例1に係る口腔内麻酔剤の容器を開封した。そして、当該歯科医師が、患者に当該口腔内麻酔剤を投与し、約10秒間ブクブクうがいをさせた後、吐き出しを指示して、直ちに口腔から吐き出させた。 The dentist opened the manufactured oral anesthetic container according to Example 1 beside the patient. Then, the dentist administered the oral anesthetic agent to the patient, gargled for about 10 seconds, instructed to discharge, and immediately discharged from the oral cavity.
 当該うがいの後、P.M.T.C、スケーリング、歯周病検査、歯垢の除去という歯科検査および歯科治療を施療した。当該患者からの聞き取り調査によれば、麻酔の効果は、うがいの後、直ちに開始された。麻酔の強度は、さほど強いものではなかったが、P.M.T.C、スケーリング、歯周病検査、歯垢の除去に伴うチクチク感や、軽度の痛みは感じなかった、との感想を得た。 After the gargle, M.M. T.A. C, Scaling, Periodontal Examination, Dental Examination and Dental Treatment of Plaque Removal. According to interviews with the patient, the effect of anesthesia began immediately after gargle. The intensity of anesthesia was not so strong. M.M. T.A. C, scaling, periodontal disease test, the tingling sensation associated with the removal of plaque and the impression that mild pain was not felt.
 次に、歯科治療を施療した歯科医師からの聞き取り調査をおこなった。すると、口腔内麻酔剤が密封保存されているので、保管や管理面で安心であること、1人の患者に1回使用する分量の口腔内麻酔剤が1パックとなっているので、使用量の過不足を確実に回避することが出来る点は優れているとの感想を得た。 Next, an interview survey was conducted with dentists who treated dental treatment. Then, since the oral anesthetic is sealed and stored, it is safe in terms of storage and management, and the amount of oral anesthetic that can be used once per patient is in one pack. The point that it was possible to avoid the excess and deficiency of was surely excellent.
 結局、患者のすぐ脇で口腔内麻酔剤調製され、当該口腔内麻酔剤をうがいするだけで、患者に対して適度な口腔内麻酔が施療される。この結果、患者、歯科医師の双方に安心感が生まれて、互いにリラックスした状態で歯科検査および歯科治療を施療することが出来た。 Eventually, an oral anesthetic is prepared right next to the patient, and appropriate oral anesthesia is treated for the patient simply by gargleing the oral anesthetic. As a result, both the patient and the dentist were relieved and were able to perform dental examination and treatment in a relaxed state.
 以上、実施例を参照しながら、P.M.T.C、スケーリング、歯周病検査、軽微な切削、歯垢の除去等の、比較的痛みの軽い歯科検査または歯科治療を例として、本発明に係る口腔内麻酔剤について説明してきた。しかし、本発明に係る口腔内麻酔剤は、口腔外科手術や耳鼻咽喉科処置に際しての麻酔剤として用いることもできる。さらに、強い痛みの伴う抜歯等の施療に先立って行われる麻酔注射の苦痛を和らげる、予備的な麻酔剤として用いることもできる。 In the above, referring to the examples, P.I. M.M. T.A. The oral anesthetic agent according to the present invention has been described by taking dental examination or dental treatment with relatively light pain such as C, scaling, periodontal disease examination, minor cutting, and plaque removal as an example. However, the intraoral anesthetic according to the present invention can also be used as an anesthetic for oral surgery and otolaryngology treatment. Furthermore, it can also be used as a preliminary anesthetic agent that relieves the pain of anesthesia injection performed prior to treatment such as extraction with strong pain.
本発明に係る口腔内麻酔剤の容器の外観である。It is an external appearance of the container of the intraoral anesthetic concerning this invention. 本発明に係る口腔内麻酔剤の異なる容器の外観である。It is an external appearance of the container from which the intraoral anesthetic concerning this invention differs. 本発明に係る口腔内麻酔剤の異なる容器の外観である。It is an external appearance of the container from which the intraoral anesthetic concerning this invention differs. 本発明に係る口腔内麻酔剤の異なる容器の外観である。It is an external appearance of the container from which the intraoral anesthetic concerning this invention differs.
   (1)容器部
   (2)蓋部
   (3)容器部
   (4)蓋部     
   (5)容器部
   (6)容器部
   (7)容器部
   (8)蓋部 
   (9)目盛り  
(1) Container part (2) Lid part (3) Container part (4) Lid part
(5) Container part (6) Container part (7) Container part (8) Lid part
(9) Scale

Claims (5)

  1.  専門家による歯面清掃、歯石除去、歯科検査、歯科治療、口腔外科手術、または、耳鼻咽喉科処置の際に用いられる液体の口腔内麻酔剤であって、
     薬事法承認取得済みの麻酔薬を含有し、
     前記1回の歯科検査または歯科治療の際に用いられる量の前記液体の口腔内麻酔剤が、外気と遮断された状態で所定の容器に充填されたものであり、
     口腔内麻酔を実施する際には、前記容器を開封して前記液体の口腔内麻酔剤患者に投与後、当該口腔内麻酔剤をうがいさせる形で施療するものであることを特徴とする口腔内麻酔剤。
    A liquid oral anesthetic used during professional tooth cleaning, tartar removal, dental examination, dental treatment, oral surgery, or otolaryngology procedures,
    Contains anesthetics approved by the Pharmaceutical Affairs Law,
    The amount of the liquid oral anesthetic used in the single dental examination or dental treatment is filled in a predetermined container in a state of being blocked from the outside air,
    When performing oral anesthesia, the container is opened and the liquid oral anesthetic agent is administered to a patient, and then the oral anesthetic agent is treated in the form of gargle. Anesthetic.
  2.  前記薬事法承認取得済みの麻酔薬に加え、薬事法承認取得済みの殺菌剤を含有していることを特徴とする請求項1に記載の口腔内麻酔剤。  The oral anesthetic according to claim 1, further comprising a fungicide approved by the Pharmaceutical Affairs Law in addition to the anesthetic approved by the Pharmaceutical Affairs Law. *
  3.  前記薬事法承認取得済みの麻酔薬として塩酸リドカインを含有していることを特徴とする請求項1または2に記載の口腔内麻酔剤。  The oral anesthetic according to claim 1 or 2, which contains lidocaine hydrochloride as an anesthetic that has been approved by the Pharmaceutical Affairs Law. *
  4.  前記薬事法承認取得済みの殺菌剤としてクロロヘキシジンを含有していることを特徴とする請求項2または3に記載の口腔内麻酔剤。  The oral anesthetic according to claim 2 or 3, which contains chlorohexidine as a bactericide that has been approved by the Pharmaceutical Affairs Law. *
  5.  前記容器として、プラスチック製のポーション容器を用いていることを特徴とする請求項1から4のいずれかに記載の口腔内麻酔剤。  The oral anesthetic according to any one of claims 1 to 4, wherein a plastic portion container is used as the container. *
PCT/JP2009/061177 2008-06-24 2009-06-19 Buccal anaesthetic WO2009157377A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010517971A JPWO2009157377A1 (en) 2008-06-24 2009-06-19 Oral anesthetic

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008-164943 2008-06-24
JP2008164943 2008-06-24

Publications (1)

Publication Number Publication Date
WO2009157377A1 true WO2009157377A1 (en) 2009-12-30

Family

ID=41444445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/061177 WO2009157377A1 (en) 2008-06-24 2009-06-19 Buccal anaesthetic

Country Status (2)

Country Link
JP (1) JPWO2009157377A1 (en)
WO (1) WO2009157377A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535793A (en) * 2013-11-11 2016-11-17 ジヴ エム.ディー. ハリシュ Formulations and methods for prevention and treatment of oral allergy syndrome

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH101441A (en) * 1996-06-14 1998-01-06 Tendou Seiyaku Kk Local anesthetic composition
JP2004113759A (en) * 2002-09-26 2004-04-15 Takao Kasahara Gargle put into disposable container
JP2005041832A (en) * 2003-07-24 2005-02-17 Medorekkusu:Kk Gargle containing local anesthetic
JP2007222270A (en) * 2006-02-22 2007-09-06 Nipro Corp Medicine package

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH101441A (en) * 1996-06-14 1998-01-06 Tendou Seiyaku Kk Local anesthetic composition
JP2004113759A (en) * 2002-09-26 2004-04-15 Takao Kasahara Gargle put into disposable container
JP2005041832A (en) * 2003-07-24 2005-02-17 Medorekkusu:Kk Gargle containing local anesthetic
JP2007222270A (en) * 2006-02-22 2007-09-06 Nipro Corp Medicine package

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535793A (en) * 2013-11-11 2016-11-17 ジヴ エム.ディー. ハリシュ Formulations and methods for prevention and treatment of oral allergy syndrome

Also Published As

Publication number Publication date
JPWO2009157377A1 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
ES2632363T3 (en) Antiseptic pharmaceutical composition for oral hygiene and the treatment of oral diseases of microbial origin
PT1280531E (en) Formulation consisting of phentolamine mesylate and the use thereof
BR112020002106B1 (en) GEL COMPOSITION, PREPARATION METHOD AND USE
CN102046140A (en) Oral hygiene composition and apparatus and method
US20080146672A1 (en) Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue
RU2550957C1 (en) Method of treating chronic generalised periodontitis
Chibinski The use of silver diamine fluoride in pediatric dentistry
WO2009157377A1 (en) Buccal anaesthetic
Thaman et al. Ozone Therapy in Conservative Dentistry and Endodontics: An Overview.
Vissink et al. Xerostomia and dental problems in the head and neck radiation patient
US20060280695A1 (en) Methods and compositions for the prevention, suppression and elimination of oral pain
RU2557920C1 (en) Method for preventing inflammatory complications in patients accompanying outpatient oral surgeries
Aboytes Topical Anesthetic Agents
Grover et al. An approach towards painless administration of local anaesthetic agents in pediatric dentistry: In vivo study
Thoma Oral Anesthesia; Local Anesthesia in the Oral Cavity: Technique and Practical Application in the Different Branches of Dentistry
Tiwari et al. ORAL MUCOCELE: A CASE REPORT.
WAHID A RESEARCH THESIS SYNOPSIS
Subburu et al. Efficacy of 7.5% Sodium Bicarbonate Buffered 2% Lidocaine with 1: 80,000 Epinephrine in Exodontia
RU2279271C2 (en) Preparation for treatment of stomatological disease
Deka et al. Untying a tongue tie using diode laser: A case report
Poddar et al. A comparative study for assessment of post-operative sequelae following mandibular transalveolar molar extractions using ozone and dexamethasone
Malamed Reversing local anesthesia
RU2323721C2 (en) Local anesthetic and antiseptic agent
SOUMYA PARMAR et al. PAIN CONTROL IN CONSERVATIVE DENTISTRY AND ENDODONTICS
WO2023096535A1 (en) Smoking cessation agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09770087

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010517971

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09770087

Country of ref document: EP

Kind code of ref document: A1